We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
35 hedge funds and large institutions have $6.46M invested in Crescent Biopharma in 2025 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
0.01% more ownership
Funds ownership: 0.47% → 0.48% (+0.01%)
15% less capital invested
Capital invested by funds: $7.56M → $6.46M (-$1.1M)
15% less funds holding
Funds holding: 41 → 35 (-6)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
54% less call options, than puts
Call options by funds: $24K | Put options by funds: $52K
Holders
35
Holders Change
-6
Holders Change %
-14.63%
% of All Funds
0.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
4
Reduced
6
Closed
12
Calls
$24K
Puts
$52K
Net Calls
-$28K
Net Calls Change
-$54K
Top Buyers
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$102K |
| 2 |
SC
Shay Capital
New York
|
+$95.5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$63.4K |
| 4 |
JFG
Jefferies Financial Group
New York
|
+$43.1K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$13.5K |
Top Sellers
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$82.6K |
| 2 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$50.9K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$16K |
| 4 |
Jane Street
New York
|
-$14.7K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$11.5K |
